COVID-19 updates and information
Our world-class experts. Your child’s care team.
Explore Our Research
Exceptional science. Innovative cures.
Give to help them live.
At just 6 years old, Eli was diagnosed with bone cancer. His family was referred to St. Jude for his treatment.
Read This Patient's Story
Cover for the kids of St. Jude. Cover for the kids in your community. Cover for the kids in your life.
Read Cover for the Kids
We have some of the world's best survival rates for some of the most aggressive cancers.
From holiday cards to online store purchases, there are many ways you can give back to St. Jude kids this holiday season.
What happens when you give the world’s brightest minds the resources to do something remarkable? Cures.
St. Jude Inspire tells the stories that inspire trust, hope and faith in the mission that drives us: Finding cures. Saving children.
Read our new strategic plan, and learn about our bold vision for the future.
Read This Article
See what celebrities like Jennifer Aniston, Sofía Vergara, Michael Strahan and Yara Shahidi are saying about their support of St. Jude.
Read This Story
We share our research with the world, leading a global effort to understand, treat, and defeat pediatric cancer and other life-threatening diseases.
Make the holidays even more special for the kids of St. Jude by sending them a virtual holiday card and message.
St. Jude phase II clinical trial results suggest monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
Researchers will present their work and share their expertise at ASH2021, the 63rd annual meeting of the American Society of Hematology.
Clinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses.
St. Jude scientists' findings were published in Cell Reports.
St. Jude Children’s Research Hospital scientists have shed light on the way ligands bind to and activate ALK, an important target for cancer drug development.
St. Jude scientists map nutrient-dependent signaling in T cells, offering possible new drug targets for treating infectious diseases, cancer and immune-mediated disorders.
St. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.
More Science & Medicine